Denali Therapeutics Past Earnings Performance
Past criteria checks 0/6
Denali Therapeutics's earnings have been declining at an average annual rate of -21.2%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 18.4% per year.
Key information
-21.2%
Earnings growth rate
-14.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 18.4% |
| Return on equity | -14.1% |
| Net Margin | -43.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Denali Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 331 | -145 | 103 | 0 |
| 30 Sep 23 | 341 | -124 | 102 | 0 |
| 30 Jun 23 | 343 | -128 | 100 | 2 |
| 31 Mar 23 | 101 | -371 | 95 | 0 |
| 31 Dec 22 | 108 | -326 | 90 | 0 |
| 30 Sep 22 | 111 | -303 | 89 | 0 |
| 30 Jun 22 | 112 | -284 | 85 | 30 |
| 31 Mar 22 | 83 | -286 | 83 | 0 |
| 31 Dec 21 | 49 | -291 | 79 | 0 |
| 30 Sep 21 | 353 | 30 | 75 | 0 |
| 30 Jun 21 | 357 | 56 | 72 | 0 |
| 31 Mar 21 | 340 | 58 | 67 | 0 |
| 31 Dec 20 | 336 | 71 | 60 | 0 |
| 30 Sep 20 | 24 | -228 | 53 | 0 |
| 30 Jun 20 | 28 | -216 | 49 | 0 |
| 31 Mar 20 | 26 | -215 | 50 | 0 |
| 31 Dec 19 | 27 | -198 | 46 | 0 |
| 30 Sep 19 | 148 | -66 | 47 | 0 |
| 30 Jun 19 | 135 | -55 | 44 | 0 |
| 31 Mar 19 | 133 | -52 | 36 | 0 |
| 31 Dec 18 | 129 | -36 | 32 | 0 |
| 30 Sep 18 | 3 | -137 | 26 | 0 |
| 30 Jun 18 | 2 | -123 | 21 | 0 |
| 31 Mar 18 | 1 | -91 | 18 | 0 |
| 31 Dec 17 | 0 | -88 | 16 | 0 |
| 30 Sep 17 | 0 | -85 | 14 | 17 |
| 30 Jun 17 | 0 | -93 | 13 | 39 |
| 31 Mar 17 | 0 | -90 | 12 | 55 |
| 31 Dec 16 | 0 | -87 | 12 | 0 |
Quality Earnings: 4DN is currently unprofitable.
Growing Profit Margin: 4DN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4DN is unprofitable, and losses have increased over the past 5 years at a rate of 21.2% per year.
Accelerating Growth: Unable to compare 4DN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4DN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: 4DN has a negative Return on Equity (-14.09%), as it is currently unprofitable.